PLRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
PLRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Pliant Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 was 4.17%.
Pliant Therapeutics's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.69.
The historical data trend for Pliant Therapeutics's YoY EPS Growth can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.
Pliant Therapeutics's YoY EPS Growth for the fiscal year that ended in Dec. 2023 is calculated as:
YoY EPS Growth (A: Dec. 2023 ) | |||||
= | (Earnings per Share (Diluted) (A: Dec. 2023 ) | - | Earnings per Share (Diluted) (A: Dec. 2022 )) | / | | Earnings per Share (Diluted) (A: Dec. 2022 ) | |
= | (-2.75 | - | -2.94) | / | | -2.94 | |
= | 6.46 % |
Pliant Therapeutics's YoY EPS Growth for the quarter that ended in Dec. 2023 is calculated as:
YoY EPS Growth (Q: Dec. 2023 ) | |||||
= | (Earnings per Share (Diluted) (Q: Dec. 2023 ) | - | Earnings per Share (Diluted) (Q: Dec. 2022 )) | / | | Earnings per Share (Diluted) (Q: Dec. 2022 )) | |
= | (-0.69 | - | -0.72) | / | | -0.72 | |
= | 4.17 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Pliant Therapeutics's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.
Hans Hull | officer: Chief Business Officer | C/O AVALANCHE BIOTECHNOLOGIES, INC., 1035 O'BRIEN DRIVE, SUITE A, MENLO PARK CA 94025 |
Eric Lefebvre | officer: Chief Medical Officer | C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, #200, SOUTH SAN FRANCISCO CA 94080 |
Keith Lamont Cummings | officer: Chief Financial Officer | C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Bernard Coulie | director, officer: President and CEO | C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Mike Ouimette | officer: General Counsel | C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Thomas A Mccourt | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Darren S Cline | director | 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140 |
Lily Cheung | officer: Chief Human Resource Officer | 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Katharine Knobil | director | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVE., LEXINGTON MA 02421 |
Pyott David E I | director | C/O ALLERGAN, 2525 DUPONT DRIVE, IRVINE CA 92612 |
Third Rock Ventures Gp Iv, L.p. | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Kevin P Starr | 10 percent owner | 29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116 |
Smital Shah | director | C/O PLIANT THERAPEUTICS, INC., 260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Suzanne Louise Bruhn | director | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
From GuruFocus
By sperokesalga 04-12-2023
By Stock market mentor 02-02-2023
By sperokesalga 03-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.